Here are the 10-K annual reports from Vericel Corporation (VCEL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow VCEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VCEL filings page.
Vericel Corporation focuses on advanced therapies for sports medicine and severe burn care, built around three marketed products: MACI for knee cartilage repair, Epicel for extensive burns, and NexoBrid for enzymatic removal of burn eschar in adults and children.
The company is expanding MACI through the arthroscopic MACI Arthro technique, now FDA‑approved and launched in 2024, and by targeting more surgeons and indications, including a pivotal ankle trial (MASCOT) and a planned UK launch via the MHRA’s recognition pathway. Its new Burlington, Massachusetts facility is intended to become the primary global manufacturing site for MACI and Epicel.
Vericel also grows its burn franchise by pairing Epicel with NexoBrid, supported by exclusive North American rights from MediWound. As of February 19, 2026, 50,763,319 common shares were outstanding, and the aggregate market value of non‑affiliate shares was about $2.1 billion as of June 30, 2025.